…
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Arcadia Biosciences develops crop trait technologies intended to improve yield, stress tolerance and nutritional quality for agricultural markets. Long-term growth drivers include rising global food demand and climate-related pressure on crop productivity, which increase demand for resilient and higher-value seeds. The company may appeal to investors seeking exposure to agricultural biotechnology and trait-based solutions.
Key risks include execution and commercialization challenges—particularly regulatory approvals, market adoption against large seed and trait competitors, and the need for external financing to fund development and scale-up.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.33M | -4.31M | -5.32M | -15.60M | -16.13M |
| Minority interest | - | 0.00M | 0.09M | 0.24M | 1.47M |
| Net income | -2.34M | -7.04M | -13.98M | -15.61M | -16.13M |
| Selling general administrative | 7.00M | 9.64M | 17.73M | 18.05M | 22.94M |
| Gross profit | 1.76M | 2.08M | 2.28M | 0.15M | -1.93M |
| Reconciled depreciation | 0.03M | 0.11M | 0.31M | 0.48M | 1.04M |
| Ebit | -2.33M | -7.61M | -6.02M | -19.40M | -35.53M |
| Ebitda | -2.30M | -7.50M | -5.73M | -22.72M | -18.36M |
| Depreciation and amortization | 0.03M | 0.11M | 0.29M | -3.32M | 17.16M |
| Operating income | -9.99M | -3.65M | -6.10M | -19.40M | -35.53M |
| Other operating expenses | 14.85M | 8.69M | 10.56M | 29.36M | 35.53M |
| Interest expense | - | - | - | 0.29M | 0.02M |
| Tax provision | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Interest income | 0.22M | 0.78M | 0.69M | - | - |
| Net interest income | 0.22M | 0.78M | 0.70M | 0.29M | -0.79M |
| Income tax expense | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Total revenue | 4.86M | 5.04M | 4.45M | 9.96M | 6.78M |
| Total operating expenses | 11.76M | 5.73M | 8.38M | 19.56M | 26.83M |
| Cost of revenue | 3.10M | 2.96M | 2.17M | 9.80M | 8.71M |
| Total other income expense net | 7.66M | -0.66M | 0.78M | 3.81M | 19.39M |
| Net income from continuing ops | -2.34M | -4.32M | -18.51M | -15.61M | -16.13M |
| Net income applicable to common shares | - | - | - | - | -14.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 6.55M | 13.52M | 19.70M | 28.92M | 43.92M |
| Intangible assets | 0.04M | 0.04M | 0.04M | 0.04M | 0.48M |
| Other current assets | 0.16M | 2.92M | 0.86M | 0.81M | 0.90M |
| Total liab | 2.41M | 7.29M | 7.00M | 8.02M | 12.72M |
| Total stockholder equity | 4.14M | 6.22M | 12.84M | 21.03M | 31.09M |
| Other current liab | 0.61M | 1.71M | 1.94M | 0.32M | 0.26M |
| Common stock | 0.07M | 0.07M | 0.07M | 0.07M | 0.06M |
| Capital stock | 0.07M | 0.07M | 0.07M | 0.07M | 0.06M |
| Retained earnings | -281.22M | -278.88M | -271.84M | -257.86M | -226.49M |
| Other liab | - | - | - | - | 5.46M |
| Good will | - | - | - | - | 0.00M |
| Other assets | - | - | 0.00M | - | 2.67M |
| Cash | 0.26M | 4.24M | 6.52M | 20.64M | 28.68M |
| Total current liabilities | 2.06M | 2.56M | 3.59M | 4.21M | 5.04M |
| Current deferred revenue | - | - | - | - | 0.06M |
| Net debt | -0.26M | -4.09M | -5.51M | -18.63M | -25.39M |
| Short term debt | - | 0.15M | 0.85M | 1.01M | 1.07M |
| Short long term debt total | - | 0.15M | 1.01M | 2.02M | 3.29M |
| Other stockholder equity | 285.29M | 285.04M | 284.51M | 278.83M | 257.51M |
| Property plant equipment | - | - | - | - | 5.37M |
| Total current assets | 6.36M | 9.24M | 14.97M | 25.40M | 35.39M |
| Net tangible assets | - | - | - | - | 30.61M |
| Short term investments | 4.30M | 0.00M | 5.12M | - | 0.00M |
| Net receivables | 0.42M | 1.18M | 0.51M | 1.29M | 1.37M |
| Inventory | 1.21M | 0.90M | 1.96M | 2.57M | 4.43M |
| Accounts payable | 1.45M | 0.70M | 0.80M | 2.88M | 3.64M |
| Accumulated other comprehensive income | - | - | 0.10M | - | - |
| Non currrent assets other | 0.14M | 4.06M | 3.52M | 0.93M | 2.67M |
| Non current assets total | 0.19M | 4.28M | 4.73M | 3.52M | 8.53M |
| Capital lease obligations | 0.00M | 0.15M | 1.01M | 2.02M | 3.29M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | 7.34M | -4.12M | 1.42M | 16.61M |
| Change to liabilities | - | - | - | - | -0.38M |
| Total cashflows from investing activities | 0.75M | 7.34M | -4.34M | - | 16.61M |
| Net borrowings | - | - | - | - | -2.15M |
| Total cash from financing activities | 0.01M | 0.01M | 5.51M | 4.52M | 21.90M |
| Change to operating activities | - | - | - | - | -1.46M |
| Net income | -2.34M | -4.32M | -13.99M | -15.61M | -16.13M |
| Change in cash | -3.98M | -2.28M | -14.13M | -8.04M | 12.64M |
| Begin period cash flow | 4.24M | 6.52M | 20.64M | 28.68M | 16.04M |
| End period cash flow | 0.26M | 4.24M | 6.52M | 20.64M | 28.68M |
| Total cash from operating activities | -4.74M | -9.63M | -15.29M | -13.98M | -25.87M |
| Issuance of capital stock | - | 0.00M | 6.00M | 5.00M | 25.15M |
| Depreciation | 0.03M | 0.77M | 0.29M | 0.48M | 1.04M |
| Other cashflows from investing activities | 0.75M | 4.00M | 0.12M | - | - |
| Change to inventory | -0.31M | 0.55M | -2.42M | 1.12M | -2.38M |
| Change to account receivables | 0.17M | -0.76M | 0.18M | 0.59M | -0.04M |
| Sale purchase of stock | - | - | - | - | 25.15M |
| Other cashflows from financing activities | 0.01M | 0.01M | -0.48M | 0.45M | -1.10M |
| Change to netincome | - | - | - | - | -9.27M |
| Capital expenditures | 0.00M | 0.02M | 0.01M | 0.07M | 1.01M |
| Change in working capital | -0.03M | -1.45M | -2.74M | 1.05M | -2.92M |
| Stock based compensation | 0.23M | 0.51M | 0.72M | 1.11M | 1.54M |
| Other non cash items | -2.64M | -4.63M | 0.43M | -1.00M | 0.49M |
| Free cash flow | -4.74M | -9.64M | -15.30M | -14.05M | -26.88M |
Sector: Consumer Defensive Industry: Packaged Foods
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RKDA Arcadia Biosciences Inc |
-0.00 0.64% |
0.15 | - | 36.63 | 0.22 | 1.64 | 0.06 | 0.62 |
| NSRGF Nestle SA |
3.65 3.63% |
104.28 | 26.86 | 18.76 | 3.13 | 7.10 | 3.81 | 21.70 |
| NSRGY Nestle SA ADR |
-0.95 0.92% |
102.44 | 26.82 | 18.66 | 3.18 | 7.07 | 3.81 | 21.70 |
| DANOY Danone PK |
-0.12 0.81% |
14.71 | 24.23 | 17.64 | 1.88 | 2.57 | 1.88 | 11.70 |
| GPDNF Danone S.A |
-0.26 0.35% |
73.62 | 20.30 | 14.75 | 1.65 | 2.24 | 1.76 | 10.92 |
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
| Name | Title | Year Born |
|---|---|---|
| Ms. Pamela Haley | CFO & Corp. Sec. | 1971 |
| Ms. Laura Pitlik | Chief Marketing Officer | 1974 |
| Mr. Stanley E. Jacot Jr. | Pres, CEO & Director | 1970 |
| Ms. Belinda Yao | VP of Operations | NA |
| Mr. Brian Schaffer | Sr. VP of Sales | NA |
| Mr. Kevin Hodges | VP of Commercial Operations | NA |
| Mr. Stanley E. Jacot Jr. | President, CEO & Director | 1971 |
| Mr. Thomas J. Schaefer | CFO & Corporate Secretary | 1976 |
| Mr. Tracy Baker | Senior Vice President of Seamless Technical Operations | NA |
| Mr. Thomas J. Schaefer C.F.A. | CEO, Interim CFO, Principal Accounting Officer, President, Corporate Secretary & Director | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.